Arrowhead Pharmaceuticals’ RNAi drug plozasiran, brand name Redemplo, is now the second FDA-approved therapy for familial chylomicronemia syndrome, an inherited lipid disorder. Beyond its claims of safety and dosing advantages, Arrowhead set a dramatically lower price for its first commercial product, which will compete against an Ionis Pharmaceuticals drug.
The post With FDA Approval for RNAi Drug, Arrowhead Pharma Starts Price War With Rival Ionis appeared first on MedCity News.
Australian, global agencies cripple major cybercrime malware tools – IT Brief Australia
Australian, global agencies cripple major cybercrime malware tools IT Brief Australia
